ClinicalTrials.gg
RecruitingNCT06091254OLYMPIA-1Updated Nov 12, 2026

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

A Phase 3 interventional study of Odronextamab and Rituximab in Follicular Lymphoma (FL), sponsored by Regeneron Pharmaceuticals. Recruiting at 190 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
822
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Lymphoma, Follicular by Regeneron Pharmaceuticals — 2 open to participants now, 4 under way, 3 of them phase 3. Lymphoma, Follicular · Regeneron Pharmaceuticals.

Planned enrollment
Largest of 10
822 · median 203
Started
2023
with 2 others
Phase 3
3 of 15
2 open now
Registered
13th of 15
by date

Among the 15 studies in Lymphoma, Follicular by Regeneron Pharmaceuticals, this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2023, is one of 3 in phase 3, and was the 13th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

2 of the 15 studies in Lymphoma, Follicular by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Lymphoma, Follicular by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL).

This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized - controlled).

The aim of Part 1 of the study is to see how safe and tolerable the study drug is when given alone.

The aim of Part 2 of the study is to see how the study drug works compared to rituximab (called the "comparator drug") and chemotherapy (the current standard of care for NHL). Standard of care means the usual medication expected and used when receiving treatment for a condition.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
  • How the study drug affects quality of life and ability to complete routine daily activities.
03

Conditions studied

  • Follicular Lymphoma (FL)

Keywords

  • Non-Hodgkin lymphomas (NHLs)
  • Indolent NHL
  • B-cells NHL (B-NHL)
  • Follicular lymphoma
  • Odronextamab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of Cluster of Differentiation 20\^+ (CD20\^+) FL Grade 1-3a, stage II bulky or stage III / IV
  2. Need for treatment as described in the protocol
  3. Have on cross-sectional imaging documented by diagnostic imaging Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)
  4. (ECOG) performance status of 0-2
  5. Adequate bone marrow function and hepatic function, as described in the protocol

Key Exclusion Criteria:

  1. Central Nervous System (CNS) lymphoma or lymphoma
  2. Histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
  3. Waldenström Macroglobulinemia (WM, lymphoplasmacytic lymphoma), Grade 3b follicular lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma
  4. Treatment with any systemic anti-lymphoma therapy
  5. Infections and allergy/ to study drug or , as described in the protocol

NOTE: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
822 participants (estimated)

Study arms

  • Experimental
    Odronextamab

    Part 1 is a safety run-in. All participants will receive odronextamab. In part 2 participants will be randomly assigned in a 1:1 ratio to receive odronextamab followed by odronextamab maintenance.

    Drug: Odronextamab

  • Active comparator
    Rituximab + Investigator's Choice Chemotherapy

    Part 2 only, participants will be randomized 1:1 to receive rituximab in combination with chemotherapy followed by rituximab maintenance.

    Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone/prednisolone · Drug: Bendamustine

Interventions

  • Administered per the protocol

    Also known as: REGN1979

  • Administered per the protocol

    Also known as: Rituxan

  • Administered per the protocol as part of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) chemotherapy, or Cyclophosphamide, Vincristine, Prednisone (CVP) chemotherapy

    Also known as: Cytoxan

  • Administered per the protocol as part of CHOP chemotherapy

    Also known as: Adriamycin

  • Administered per the protocol as part of CHOP, and CVP chemotherapy

    Also known as: Oncovin

  • DrugPrednisone/prednisolone

    Drug pages: Prednisone · Prednisolone

    Administered per the protocol as part of CVP chemotherapy

    Also known as: Deltasone/Omnipred

  • Administered per the protocol as part of chemotherapy (Rituximab-Bendamustine)

    Also known as: Treanda

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLTs) for odronextamab

    Part 1

    Time frame: Up to 35 days

  2. Incidence of Treatment-Emergent Adverse Events (TEAEs) of odronextamab

    Part 1

    Time frame: Up to 2 years

  3. Severity of TEAEs of odronextamab

    Part 1

    Time frame: Up to 2 years

  4. Complete Response at 30 months (CR30) as assessed by independent central review

    Part 2

    Time frame: Up to 30 months

Secondary outcomes

  1. Concentrations of odronextamab in serum

    Part 1

    Time frame: Up to 30 months

  2. Occurrence of Anti-Drug Antibodies (ADAs) to odronextamab

    Part 1

    Time frame: Up to 30 months

  3. Magnitude of ADAs to odronextamab

    Part 1

    Time frame: Up to 30 months

  4. Objective response as assessed by the investigator

    Part 1

    Time frame: Up to 30 months

  5. Progression-Free Survival (PFS) as assessed by independent central review

    Part 2

    Time frame: Up to 5 years

  6. Event-Free Survival (EFS) as assessed by independent central review

    Part 2

    Time frame: Up to 5 years

  7. Overall Survival (OS)

    Part 2

    Time frame: Up to 5 years

  8. Overall mean change in physical function [European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC-QLQ-C30)]

    Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

    Time frame: Up to 5 years

  9. CR30 as assessed by local investigator

    Part 2

    Time frame: Up to 30 months

  10. PFS as assessed by the local investigator

    Part 2

    Time frame: Up to 5 years

  11. EFS as assessed by the local investigator

    Part 2

    Time frame: Up to 5 years

  12. Objective response assessed by local investigator

    Part 2

    Time frame: Up to 30 months

  13. Objective response assessed by independent central review

    Part 2

    Time frame: Up to 30 months

  14. Duration Of Response (DOR) assessed by independent central review

    Part 2

    Time frame: Up to 5 years

  15. DOR assessed by local investigator

    Part 2

    Time frame: Up to 5 years

  16. Time To Next anti-lymphoma Treatment (TTNT)

    Part 2

    Time frame: Up to 5 years

  17. Incidence of TEAEs

    Part 2

    Time frame: Up to 2 years

  18. Severity of TEAEs

    Part 2

    Time frame: Up to 2 years

  19. Odronextamab concentrations in serum during the induction period

    Part 2

    Time frame: Up to 30 months

  20. Odronextamab concentrations in serum during the maintenance period

    Part 2

    Time frame: Up to 30 months

  21. Occurrence of ADAs to odronextamab

    Part 2

    Time frame: Up to 30 months

  22. Magnitude of ADAs to odronextamab

    Part 2

    Time frame: Up to 30 months

  23. Overall mean changes in scores of patient reported outcomes (PROs), as measured by the validated instruments EORTCQLQ- C30

    Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

    Time frame: Up to 5 years

  24. Overall mean changes in scores of PROs, as measured by the validated instruments Functional Assessment of Cancer Therapy-Lymphoma (FACT-LymS)

    Part 2 The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life.

    Time frame: Up to 5 years

  25. Overall mean changes in scores of PROs, as measured by the validated instruments EuroQol-5 Dimension-5 Level Scale (EQ-5D- 5L)

    Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state".

    Time frame: Up to 5 years

  26. Change in Patient Global Impression of Severity (PGIS)

    Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe).

    Time frame: Up to 5 years

  27. Change in Patient Global Impression of Change (PGIC)

    Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse.

    Time frame: Up to 5 years

  28. Change in score of the GP5 item in the participant population

    Part 2 A single item Global Population item 5 (GP5) of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4).

    Time frame: Up to 5 years

07

Study locations

145 of 190 sites recruiting

Showing the first 100 of 190 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Feb 2028, 50 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's planned 50 months is close to that.

Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2023
First posted
Oct 19, 2023
StartActual
Dec 12, 2023
Primary completionEst.
Feb 29, 2028
CompletionEst.
Nov 30, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Aidport Sp. z o.o. · Skorzewo, Poland
Show 1 removed
  • Aidport · Skorzewo, Poland
Oct 6, 2026
Primary completion
Feb 7, 2028→Feb 29, 2028
Nov 12, 2026
Study completion
Nov 3, 2029→Nov 30, 2029
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Primary completion Feb 7, 2028→Feb 29, 2028
    Study completion Nov 3, 2029→Nov 30, 2029
    + 1 other change: site details
  2. Oct 6, 2026
    1 site added, 1 site removed
    Show site
    • Aidport Sp. z o.o. · Skorzewo, Poland
    Show 1 removed
    • Aidport · Skorzewo, Poland
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06091254
Responsible party
Sponsor
First posted
Oct 19, 2023
Start date
Dec 12, 2023
Primary completion
Feb 29, 2028 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Odronextamab

Start the discussion